IDEXX Laboratories - IDXX Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IDXX shares.
View IDXX analyst ratings or view top-rated stocks.

9 brokerages have issued twelve-month target prices for IDEXX Laboratories' shares. Their IDXX share price forecasts range from $415.00 to $582.00. On average, they expect the company's stock price to reach $485.00 in the next year. This suggests a possible upside of 0.9% from the stock's current price.
View analysts price targets for IDXX or view top-rated stocks among Wall Street analysts.

IDEXX Laboratories' stock was trading at $407.96 at the beginning of 2023. Since then, IDXX stock has increased by 17.8% and is now trading at $480.50.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 6th 2023.
View our IDXX earnings forecast.

IDEXX Laboratories will be holding an earnings conference call on Monday, February 6th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its quarterly earnings results on Tuesday, November, 2nd. The company reported $2.03 EPS for the quarter, beating analysts' consensus estimates of $1.88 by $0.15. The firm had revenue of $810.42 million for the quarter, compared to analyst estimates of $793.26 million. IDEXX Laboratories had a trailing twelve-month return on equity of 118.38% and a net margin of 20.05%. During the same quarter last year, the business earned $1.69 EPS.
Read the conference call transcript.

IDEXX Laboratories issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of $7.74-$7.98 for the period, compared to the consensus estimate of $7.95. The company issued revenue guidance of $3.33 billion-$3.37 billion, compared to the consensus revenue estimate of $3.37 billion.

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories' stock is owned by a number of institutional and retail investors. Top institutional investors include LGT Capital Partners LTD. (0.38%), UMB Bank n.a. (0.34%), Sumitomo Mitsui Trust Holdings Inc. (0.30%), Manning & Napier Group LLC (0.21%), Bank Julius Baer & Co. Ltd Zurich (0.20%) and Riverbridge Partners LLC (0.15%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends.

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IDXX stock can currently be purchased for approximately $480.50.

IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $39.80 billion and generates $3.22 billion in revenue each year. The company earns $744.84 million in net income (profit) each year or $7.87 on an earnings per share basis.

The company employs 10,350 workers across the globe.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346.